Effects of MDMA and related analogs on plasma 5-HT: Relevance to 5-HT transporters in blood and brain

European Journal of Pharmacology

Volumn 674, Issue 2-3, 2012, Pages 337-344

  Yubero Lahoz, Samanta ^a,b   Ayestas Jr , Mario A ^c   Blough, Bruce E ^d   Partilla, John S ^c   Rothman, Richard B ^c   De La Torre, Rafael ^a,b   Baumann, Michael H ^c  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^d RTI INTERNATIONAL   (United States)

Author keywords

5 HT (serotonin); Blood; Brain; MDMA; Microdialysis; Platelet; SERT (serotonin transporter)

Indexed keywords

3 O METHYL ALPHA METHYLDOPAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; AMPHETAMINE DERIVATIVE; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN SYNAPTOSOME; CONTROLLED STUDY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT; SEROTONIN BLOOD LEVEL; SEROTONIN BRAIN LEVEL;

ANIMALS; BRAIN; MALE; MICRODIALYSIS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; PROTEIN TRANSPORT; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 84855523883     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.10.033     Document Type: Article

References (37)

1. Baumann, M.H., Wang, X., Rothman, R.B., 2007. 3,4- Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings. Psychopharmacology 189, 407-424. (Pubitemid 44791212)
2. Baumann, M.H., Clark, R.D., Franken, F.H., Rutter, J.J., Rothman, R.B., 2008. Tolerance to 3,4-methylenedioxymethamphetamine (MDMA) in rats exposed to single high-dose binges. Neuroscience 152, 773-784.
3. Baumann, M.H., Zolkowska, D., Kim, I., Scheidweiler, K.B., Rothman, R.B., Huestis, M.A., 2009. Effects of dose and route of administration on pharmacokinetics of (+/-)-3,4-methylenedioxymethamphetamine in the rat. Drug Metab. Dispos. 37, 2163-2170.
4. Chin, K.M., Channick, R.N., Rubin, L.J., 2006. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension? Chest 130, 1657-1663. (Pubitemid 46033416)
5. Crespi, D., Mennini, T., Gobbi, M., 1997. Carrier-dependent and Ca(2+)-dependent 5-HT and dopamine release induced by (+)-amphetamine, 3,4-methylendioxymethamphetamine, p-chloroamphetamine and (+)-fenfluramine. Br. J. Pharmacol. 121, 1735-1743. (Pubitemid 27343404)
6. de la Torre, R., Farre, M., Roset, P.N., Pizarro, N., Abanades, S., Segura, M., Segura, J., Cami, J., 2004. Human pharmacology of MDMA: pharmacokinetics, metabolism, and disposition. Ther. Drug Monit. 26, 137-144. (Pubitemid 38501207)
7. Dempsie, Y., MacLean, M.R., 2008. Pulmonary hypertension: therapeutic targets within the serotonin system. Br. J. Pharmacol. 155, 455-462.
8. Elkving, B., Madsen, J., Knudsen, G.M., 2007. Neuroimaging of the serotonin reuptake site requires high-affinity ligands. Synapse 61, 882-888. (Pubitemid 47464084)
9. Escobedo, I., O'Shea, E., Orio, L., Sanchez, V., Segura, M., de la Torre, R., Farre, M., Green, A.R., Colado, M.I., 2005. A comparative study on the acute and long-term effects of MDMA and 3,4-dihydroxymethamphetamine on brain monoamine levels after i.p. or striatal administration in mice. Br. J. Pharmacol. 144, 231-241. (Pubitemid 40216121)
10. Fantegrossi, W.E., Murai, N., Mathúna, B.O., Pizarro, N., de la Torre, R., 2009. Discriminative stimulus effects of 3,4- methylenedioxymethamphetamine and its enantiomers in mice: pharmacokinetic considerations. J. Pharmacol. Exp. Ther. 329, 1006-1015.
11. Forsling, M.L., Fallon, J.K., Shah, D., Tilbrook, G.S., Cowan, D.A., Kicman, A.T., Hutt, A.J., 2002. The effect of 3,4-methylenedioxymethamphetamine (MDMA, 'ecstasy') and its metabolites on neurohypophysial hormone release from isolated rat hypothalamus. Br. J. Pharmacol. 135, 649-658.
12. Goni-Allo, B., Mathuna, B.O., Segura, M., Puerta, E., Lasheras, B., de la Torre, R., Aguirre, N., 2008. The relationship between core body temperature and 3,4-methylenedioxymethamphetamine metabolism in rats: implications for neurotoxicity. Psychopharmacology 197, 263-278.
13. Gudelsky, G.A., Nash, J.F., 1996. Carrier-mediated release of serotonin by 3,4-methylenedioxymethamphetamine: implications for serotonin-dopamine interactions. J. Neurochem. 66, 243-249.
14. Heinz, A., Jones, D.W., Mazzanti, C., Goldman, D., Ragan, P., Hommer, D., Linnoila, M., Weinberger, D.R., 2000. A relationship between serotonin transporter genotype, in vivo protein expression and alcohol neurotoxicity. Biol. Psychiatry 47, 643-649. (Pubitemid 30169258)
15. Herve, P., Launay, J.M., Scrobohaci, M.L., Brenot, F., Simonneau, G., Petitpretz, P., Poubeau, P., Cerrina, J., Duroux, P., Drouet, L., 1995. Increased plasma serotonin in primary pulmonary hypertension. Am. J. Med. 99, 249-254.
16. Huang, Y., Zheng, M.Q., Gerdes, J.M., 2010. Development of effective PET and SPECT imaging agents for the serotonin transporter: has a twenty-year journey reached its destination? Curr. Top. Med. Chem. 10, 1499-1526.
17. Kolbrich, E.A., Goodwin, R.S., Gorelick, D.A., Hayes, R.J., Stein, E.A., Huestis, M.A., 2008. Plasma pharmacokinetics of 3,4- methylenedioxymethamphetamine after controlled oral administration to young adults. Ther. Drug Monit. 30, 320-332.
18. Liechti, M.E., Vollenweider, F.X., 2001. Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum. Psychopharmacol. 16, 589-598. (Pubitemid 34036939)
19. Matthews, J.N., Altman, D.G., Campbell, M.J., Royston, P., 1990. Analysis of serial measurements in medical research. Br. Med. J. 333, 230-235. (Pubitemid 20045528)
20. Mercado, C.P., Kilic, F., 2010. Molecular mechanisms of SERT in platelets: regulation of plasma serotonin levels. Mol. Interv. 10, 231-241.
21. Ni, W., Watt, S.W., 2006. 5-Hydroxytryptamine in the cardiovascular system: focus on the serotonin transporter (SERT). Clin. Exp. Pharmacol. Physiol. 33, 575-583. (Pubitemid 43894017)
22. Nobile, M., Begni, B., Giorda, R., Frigerio, A., Marino, C., Molteni, M., Ferrarese, C., Battaglia, M., 1999. Effects of serotonin transporter promoter genotype on platelet serotonin transporter functionality in depressed children and adolescents. J. Am. Acad. Child Adolesc. 38, 1396-1402. (Pubitemid 29513397)
23. Parrott, A.C., 2001. Human psychopharmacology of ecstasy (MDMA): a review of 15 years of empirical research. Hum. Psychopharmacol. 16, 557-577. (Pubitemid 34040989)
24. Ramamoorthy, S., Bauman, A.L., Moore, K.R., Han, H., Yang-Feng, T., Chang, A.S., Ganapathy, V., Blakely, R.D., 1993. Antidepressant- and cocaine-sensitive human serotonin transporter: molecular cloning, expression, and chromosomal localization. Proc. Natl. Acad. Sci. 90, 2542-2546. (Pubitemid 23078664)
25. Rausch, J.L., Johnson, M.E., Li, J., Hutcheson, J., Carr, B.M., Corley, K.M., Gowans, A.B., Smith, J., 2005. Serotonin transport kinetics correlated between human platelets and brain synaptosomes. Psychopharmacology 180, 391-398. (Pubitemid 40905028)
26. Robertson, S.D., Matthies, H.J.G., Galli, A., 2009. A closer look at amphetamine-induced reverse transport and trafficking of the dopamine and norepinephrine transporters. Mol. Neurobiol. 39, 73-80.
27. Rothman, R.B., Baumann, M.H., 2007. Methamphetamine and idiopathic pulmonary arterial hypertension: role of the serotonin transporter. Chest 132, 1412-1413. (Pubitemid 47621034)
28. Rothman, R.B., Ayestas, M.A., Dersch, C.M., Baumann, M.H., 1999. Aminorex, fenfluramine and chlorphentermine are serotonin transporter substrates. Implications for pulmonary hypertension. Circulation 100, 869-875. (Pubitemid 29398887)
29. Rothman, R.B., Baumann, M.H., Dersch, C.M., Romero, D.V., Rice, K.C., Carroll, F.I., Partilla, J.S., 2001. Amphetamine-type central nervous system stimulants release norepinephrine more potently than they release dopamine and serotonin. Synapse 39, 32-41.
30. Rothman, R.B., Vu, N., Partilla, J.S., Roth, B.L., Hufeisen, S.J., Compton-Toth, B.A., Birkes, J., Young, R., Glennon, R.A., 2003. In vitro characterization of ephedrine stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J. Pharmacol. Exp. Ther. 307, 138-145. (Pubitemid 37151899)
31. Rudnick, G., Wall, S.C., 1992. The molecular mechanism of "ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release. Proc. Natl. Acad. Sci. 89, 1817-1821.
32. Schuldiner, S., Steiner-Mordoch, S., Yelin, R., Wall, S.C., Rudnick, G., 1993. Amphetamine derivatives interact with both plasma membrane and secretory vesicle biogenic amine transporters. Mol. Pharmacol. 44, 1227-1231. (Pubitemid 24008607)
33. - coupled neurotransmitter transporters: why amphetamines take two to tango. J. Neurochem. 112, 340-355.
34. 123I]-ADAM SPECT and serotonergic measurements in platelets. Neurosci. Lett. 406, 153-158.
35. Verrico, C.D., Miller, G.M., Madras, B.K., 2007. MDMA (Ecstasy) and human dopamine, norepinephrine and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment. Psychopharmacology 189, 489-503. (Pubitemid 44791219)
36. Viisoreanu, D., Gear, A., 2007. Effect of physiologic shear stresses and calcium on agonist-induced platelet aggregation, secretion and thromboxane A2 formation. Thromb. Res. 120, 885-892. (Pubitemid 47418229)
37. Zolkowska, D., Rothman, R.B., Baumann, M.H., 2006. Amphetamine analogs increase plasma serotonin: implications for cardiac and pulmonary disease. J. Pharmacol. Exp. Ther. 318, 604-610. (Pubitemid 44061235)